Tennessee | 001-15875 | 54-1684963 | ||
(State or Other Jurisdiction | (Commission | (I.R.S. Employer | ||
of Incorporation) | File Number) | Identification No.) |
501 Fifth Street, | 37620 | |
Bristol, Tennessee | (Zip Code) | |
(Address of Principal Executive Offices) |
o | Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
x | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 8.01. | Other Events. |
Item 9.01. | Financial Statements and Exhibits. |
99.1 | King Pharmaceuticals, Inc. Press Release, dated August 22, 2008. |
KING PHARMACEUTICALS, INC |
||||
By: | /s/ Joseph Squicciarino | |||
Joseph Squicciarino | ||||
Chief Financial Officer | ||||
Exhibit No. | Description | |||
99.1 | King Pharmaceuticals, Inc. Press Release, dated August 22, 2008. |